What Sparked AbCellera Biologics To Soar Over 9% After Hours
AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trending on Wednesday.
Earnings Beat Drives After-Hours Rally
Shares of the Vancouver-based biotechnology company rose 9.32% in after-hours trading on Tuesday to $3.52 after the company reported its fourth-quarter 2025 earnings.
AbCellera Biologics posted earnings per share of negative $0.03, compared with an estimate of negative $0.18, representing an 83.33% earnings outperformance.
Its revenue also increased by $39.80 million from a year earlier.
The fourth-quarter results follow a challenging third quarter of 2025, when ABCL missed earnings per share estimates by $0.02.
Trading Metrics, Technical Analysis
AbCellera Biologics has a market capitalization of $963.86 million, with a 52-week high of $6.52 and a 52-week low of $1.89.
It has a Relative Strength Index (RSI) of 44.92.
The stock of the clinical-stage company has delivered a 14.18% gain over the past 12 months.
Price Action: ABCL closed on Tuesday up 6.27% at $3.22, according to Benzinga Pro data.
The stock is about 28.7% above its 52-week low, closer to the lower end of its annual range.
Benzinga's Edge Stock Rankings indicate that ABCL has a negative price trend across all time frames.
Photo courtesy: santima.studio / Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Dell executive: "Agent AI" is different this time, key components (mainly memory and HDD) shortages may last for more than 5 years
Dell Technologies Chief Operating Officer Jeff Clarke stated that proxy AI, by taking on more tasks, continues to drive up computing and storage demands, making this AI infrastructure cycle distinct from traditional hardware upgrade cycles. By 2030, data center computing power is expected to increase by 200 GW, inference token generation will grow 87-fold, and infrastructure demand is likely to continue expanding.
Morgan Stanley Backs Meta (META.US): Muse Ecosystem Continues to Expand, VR Glasses Expected to Become a New Growth Point in 2027
Morgan Stanley maintains an "Overweight" rating on Meta with a target price of $775, and continues to list it as a top pick.
Essay: The Next Step in AI Investment—Who Can Turn Computing Power into Profit?
Meta (META.US) surged 36% in September: Muse validates AI strategy, market cap targets $2 trillion
Meta's stock is on track to achieve its best monthly performance since July 2013, and is only about a 1% increase away from joining the $2 trillion market cap club.
Crypto prices
More
